Thursday, May 8, 2014
Publication and contact
Androgen receptor; bromodomain
containing 4 (BRD4)
Mouse and cell culture
studies suggest BRD4 inhibitors could be more effective than androgen
receptor antagonists at treating castration-resistant prostate cancer (CRPC).
In a human CRPC cell line, the BRD4 inhibitor JQ1
caused more potent suppression of androgen receptor-mediated gene
transcription than the androgen receptor antagonist Xtandi
In a mouse xenograft model of human CRPC, JQ1 caused more potent tumor growth
inhibition than Xtandi or vehicle. Next steps include developing a strategy
to identify patients that would respond to BET bromodomain inhibitors in
prostate and other cancers.
Medivation Inc. and Astellas
Pharma Inc. market Xtandi to treat prostate cancer.
The corresponding author is a cofounder of OncoFusion
Therapeutics Inc., which is collaborating with Medivation
to evaluate OncoFusion's preclinical BET bromodomain inhibitors in
undisclosed cancers and other indications.
At least four other companies have BET bromodomain inhibitors in Phase I
testing to treat various cancers.
JQ1 is a research reagent (see BETting on OncoFusion, page 1).
Published online May 8, 2014
patents filed; licensed to Medivation
Asangani, I.A. et al.
Nature; published online April 23, 2014;
Contact: Arul M. Chinnaiyan, University of Michigan Medical
School, Ann Arbor, Mich.
All contents Copyright © 1993-2017 BioCentury Publications, Inc. ALL RIGHTS RESERVED. All use of this Web Site and its contents is governed by the BioCentury User Agreement
. The contents of this Web Site are protected under U.S. and foreign copyright and intellectual property laws, and no part of this Web Site or its contents may be photocopied, reproduced or retransmitted in any form without the written consent of BioCentury, which may be requested from Reprints/Permissions
. BioCentury®; The Bernstein Report on BioBusiness™; The BioCentury 100™; The Clear Route to ROI™; Because Real Intelligence is Hard to Find™; BCIQ™; and BioPharma's Knowledge Center™; are trademarks of BioCentury Publications, Inc., P.O. Box 1246, San Carlos, CA 94070. SciBX® and SciBX: Science-Business eXchange® are trademarks of Nature America, Inc. that are jointly used by BioCentury Publications, Inc. and Nature America, Inc.
Thanks for purchasing this article.
Please bookmark this url for future reference.
We have also sent you a confirming e-mail with a receipt and this same url for your
close [ X ]